University of Texas's MD Anderson Cancer Center: NK Cells Combined With Bispecific Antibody Showed Strong Response for Patients With Lymphoma
April 11, 2022
April 11, 2022
HOUSTON, Texas, April 11 (TNSRes) -- The University of Texas's MD Anderson Cancer Center issued the following news release on April 10, 2022:
* * *
MD Anderson-led study is first clinical trial of NK cells with Affimed's AFM13 for CD30+ lymphoma
* * *
Researchers from The University of Texas MD Anderson Cancer Center showed that natural killer (NK) cells derived from donated umbilical cord blood, combined with a novel bispecific antib . . .
* * *
MD Anderson-led study is first clinical trial of NK cells with Affimed's AFM13 for CD30+ lymphoma
* * *
Researchers from The University of Texas MD Anderson Cancer Center showed that natural killer (NK) cells derived from donated umbilical cord blood, combined with a novel bispecific antib . . .